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Introduction {#bjs550227-sec-0005}
============

Open abdominal surgery is performed routinely for a number of diseases; however, it can be complicated by postoperative ileus, infection, anastomotic leak and, in the long term, bowel obstruction. Open surgery exposes the intestine to ambient air (20°C, 0--5 per cent relative humidity), which, combined with operating theatre negative air ventilation, has the potential to cause serosal/peritoneal desiccation[1](#bjs550227-bib-0001){ref-type="ref"}. Peritoneal desiccation leads to peritoneal inflammation and loss of barrier function, and increases the risk of infection[1](#bjs550227-bib-0001){ref-type="ref"}, [2](#bjs550227-bib-0002){ref-type="ref"}, [3](#bjs550227-bib-0003){ref-type="ref"}, [4](#bjs550227-bib-0004){ref-type="ref"}. In addition, peritoneal inflammation can lead to adhesion formation and subsequent bowel obstruction[1](#bjs550227-bib-0001){ref-type="ref"}, [2](#bjs550227-bib-0002){ref-type="ref"}. Bowel desiccation may also be a factor in delaying the return of bowel function after surgery. Moreover, exposure can lead to vasoconstriction of splanchnic blood flow to the intestine. Previous studies[2](#bjs550227-bib-0002){ref-type="ref"}, [3](#bjs550227-bib-0003){ref-type="ref"}, [4](#bjs550227-bib-0004){ref-type="ref"} have indicated that desiccation and cooling of the peritoneum from open surgical wounds or the use of cold, non‐humidified carbon dioxide insufflation may stimulate oxidative stress in peritoneal mesothelial cells. Thus, desiccation of the peritoneum may lead to peritoneal inflammation, which may manifest as oxidative damage and reduced splanchnic blood flow, with associated long‐term consequences.

One pathway for mitigating bowel desiccation is the use of humidified, warmed carbon dioxide gas. Carbon dioxide is heavier (44 g/mol) and denser (1·97 kg/m^3^) than the other components of atmospheric air[5](#bjs550227-bib-0005){ref-type="ref"} at standard temperature and pressure. Insufflated carbon dioxide therefore tends to sink to the base of the abdominal wound. Furthermore, carbon dioxide assists in maintaining heat by creating a localized greenhouse effect within the abdominal cavity, and is readily saturated to 100 per cent with sterile water, thereby acting to inhibit bowel desiccation[1](#bjs550227-bib-0001){ref-type="ref"}, [2](#bjs550227-bib-0002){ref-type="ref"}, [4](#bjs550227-bib-0004){ref-type="ref"}, [6](#bjs550227-bib-0006){ref-type="ref"}, [7](#bjs550227-bib-0007){ref-type="ref"}. A recently published study[8](#bjs550227-bib-0008){ref-type="ref"} that examined the effect of warmed, humidified carbon dioxide in simulated open abdominal surgery in mice found that peritoneal tissue damage, as determined by cellular retraction, bulging and microvillus damage, was significantly reduced in animals receiving warmed, humidified carbon dioxide compared with that in the standard laparotomy group.

The research question of the present study was whether peritoneal damage and inflammation are elicited during open abdominal operation, and whether the use of warmed, humidified carbon dioxide inhibits peritoneal damage. The primary aim was to investigate several markers of peritoneal inflammation and oxidative damage at the beginning and end of the surgical procedures in patients treated with warmed, humidified carbon dioxide (WHCO~2~ group) and in controls. A secondary aim was to evaluate the perioperative clinical outcomes in both groups.

Methods {#bjs550227-sec-0006}
=======

A single‐blind RCT was performed at a tertiary colorectal unit in Sydney (Concord Repatriation General Hospital, University of Sydney). The study group received warmed (37°C), humidified (98 per cent relative humidity) carbon dioxide gas. The control group received current standard practice, and no gas was insufflated into the open laparotomy wound.

Inclusion criteria {#bjs550227-sec-0007}
------------------

Patients recruited into the study were aged more than 18 years and scheduled for elective resection via a midline laparotomy. Surgical indications included: potentially curable colorectal carcinoma, polyposis syndrome, diverticular disease, rectal prolapse and inflammatory bowel disease. Patients were excluded if they had emergency surgery, laparoscopic surgery and/or presented with chronic obstructive pulmonary disease (COPD) requiring home oxygen, were carbon dioxide retainers, or if it was determined that their forced expiratory volume in 1 s (FEV1) was less than 1 litre, or predicted FEV1/forced vital capacity ratio was below 50 per cent.

Primary and secondary outcomes {#bjs550227-sec-0008}
------------------------------

The primary outcome measure was an increased degree of peritoneal inflammation and damage from the beginning to the end of operation. This included changes in levels of inflammatory cytokines, measurement of peritoneal tissue apoptosis and oxidative damage, visualization of the injury to peritoneum via light microscopy and immunofluorescence. A secondary outcome measure was the perioperative clinical result.

Patient cohort and randomization {#bjs550227-sec-0009}
--------------------------------

Patients undergoing elective surgery at Concord Hospital were eligible for the study. Ethics board approval was obtained and the trial was registered in <http://clinicaltrials.org> (NCT02975947). All patients were screened before surgery, and the trial rationale and procedure were explained carefully. Patients were then given an 'opt in' participant information sheet, after which written informed consent was obtained before final enrolment. Patients were randomized to the intervention and control arm by random sequence, generated using an online tool (<http://www.random.org>)[9](#bjs550227-bib-0009){ref-type="ref"}. Patient allocation to specific groups was concealed in opaque numbered envelopes and kept in a central location to be opened at the time of surgery. Both patients and investigators performing the analyses were blinded to the allocation.

The humidification system {#bjs550227-sec-0010}
-------------------------

HumiGard™ (Fisher & Paykel Healthcare, Auckland, New Zealand) was used to deliver warmed, humidified carbon dioxide with the gas diffuser positioned at the upper end of the laparotomy wound at a depth of approximately 4 cm from skin after the wound retractors had been placed. Insufflation of carbon dioxide was continued until the laparotomy wound had been closed. The carbon dioxide was delivered at a rate of 10 l/min, at a pressure of 4·5 bar from pressurized gas cylinders, and then passed through the HumiGard™ system.

Clinical records {#bjs550227-sec-0011}
----------------

Details of patient demographics (age, sex, co‐morbidity, level of mobility, BMI and ASA grade) and intraoperative information including the procedure performed, duration of surgery, number of assistants, duration and volume of carbon dioxide administered, intraoperative blood transfusion, intraoperative complications, allocation to an enhanced recovery after surgery (ERAS) protocol, and stoma formation were collected and used for statistical analysis. Core body temperature was measured throughout the operation using a transoesophageal probe.

Specimen collection and treatment {#bjs550227-sec-0012}
---------------------------------

Two peritoneal biopsies (1 cm^2^) were taken at the beginning (T~0~) and end of the operation before wound closure (T~end~) from the hepatorenal angle. All specimens were stored in 1·5‐ml capped tubes (Eppendorf, Hamburg, Germany), snap‐frozen in liquid nitrogen and stored at −80°C until required for biochemical or histological assessment. One of the two T~0~ and T~end~ specimens was homogenized. Samples were thawed at 20°C and the tissue was transferred into a glass tube containing 1 ml of buffer A, which consisted of: phosphate‐buffered saline (Sigma‐Aldrich, Sydney, Australia), cOmplete™ EDTA‐free Protease Inhibitor Cocktail (Sigma‐Aldrich), EDTA (Sigma‐Aldrich) and the water‐miscible phenolic antioxidant butylated hydroxyl toluene (Acros Organics, Morris Plains, New Jersey, USA) to inhibit the artificial oxidative tissue processes. Preparations of buffer A were used for a maximum of 3 months, and subsequently replaced with freshly prepared solutions to ensure optimal antioxidant activity of constituents.

The tissue was homogenized using a matched rotating piston (set to operate at 500 r.p.m.) and matching Teflon (DuPont, Stevenage, UK)‐coated glass tube, as described previously for human[10](#bjs550227-bib-0010){ref-type="ref"} and animal[11](#bjs550227-bib-0011){ref-type="ref"} tissues. The specimen was ground by the rotating piston initially for 1 min, cooled on ice (4°C) and then homogenized for a further 1 min. Finally, the tissue homogenates were aliquoted into 1·5‐ml capped tubes and stored at −80°C until required for biochemical analysis.

Markers of peritoneal inflammation and oxidative damage {#bjs550227-sec-0013}
-------------------------------------------------------

### *Tissue cytokines and chemokines* {#bjs550227-sec-0014}

Levels of inflammatory cytokines and chemokines were measured using a commercial enzyme‐linked immunosorbent assay kit (Human cytokine (16 plex)/chemokine (9 plex) -- Stripwell Chemiluminescent kit; Quansys Biosciences, Logan, Utah, USA) according to the manufacturer recommendations[12](#bjs550227-bib-0012){ref-type="ref"}, [13](#bjs550227-bib-0013){ref-type="ref"}; each peritoneal homogenate was assayed in duplicate. The analysis required a chemiluminescent imaging platform (ChemiDoc™ XRS; Life Science Research, Bio‐Rad Laboratories, Hercules, California, USA) to image the multiplex assay plates. Quantitative analysis was performed using Q‐View™ Software (Quansys Biosciences). Measurements were made of the mean fold increase in cytokine/chemokines from the samples taken at T~0~ and T~end~. The total protein concentration in each homogenate was determined using bicinchoninic acid protein analysis, and used to normalize all biochemical parameters in the corresponding homogenate. The mean T~0~ value in the control group was used as a reference point to calculate the fold increase in other groups (control group T~end~, WHCO~2~ group T~0~ and T~end~). In addition, to compare the change in level of cytokines between WHCO~2~ and control groups, the log of T~end~/T~0~ was used. T~end~ values were divided by T~0~ values, then log (base 2) was applied and the values for the two groups were compared.

### *Apoptosis* {#bjs550227-sec-0015}

Cell apoptosis was measured by detection of active caspase‐3/7 bioluminescence, assayed in the stored tissue homogenates with Caspase‐Glo® 3/7 Assay (Promega, Madison, Wisconsin, USA)[14](#bjs550227-bib-0014){ref-type="ref"}. The log(T~end~/T~0~) values for WHCO~2~ and control groups were compared. A second marker of cell viability was determined using the DeadEnd™ Fluorometric TUNEL System (Promega). The extent of DNA fragmentation (a surrogate marker for apoptosis) was quantified by the measurement of green fluorescence intensity with fluorescence microscopy. A counterstain using DAPI (4′‐6‐diamidino‐2‐phenylindole) was performed and detected as blue fluorescence. Images were captured using Zeiss Axio AX10 light microscopy (Carl Zeiss, Oberkochen, Germany) with fluorescence camera AxioCam ICm 1 (Carl Zeiss). TUNEL (terminal deoxynucleotidyl transferase‐mediated dUTP nick‐end labelling)‐stained images were reviewed by five scientists/pathologists independently, who were all blinded to sample identity, and the results analysed.

### *Estimation of peritoneal protein damage* {#bjs550227-sec-0016}

To assess peritoneal protein damage, the level of 3‐chlorotyrosine (Cl‐Tyr) and total native tyrosine (Tyr) in the peritoneal homogenates was measured by high‐pressure liquid chromatography with mass spectrometry (HPLC‐MS). Halogenated molecules can serve as specific markers for pathological oxidation as a limited number of reactive hypohalous acids participate in protein oxidation, including hypochlorous, hypobromous and hypothiocyanous acids[15](#bjs550227-bib-0015){ref-type="ref"}, [16](#bjs550227-bib-0016){ref-type="ref"}, [17](#bjs550227-bib-0017){ref-type="ref"}. The biological oxidant and antimicrobial agent hypochlorous acid is generated by myeloperoxidase[18](#bjs550227-bib-0018){ref-type="ref"}. Recent studies have demonstrated that the Cl‐Tyr/Tyr ratio is a specific marker for myeloperoxidase‐catalysed chlorination at sites of inflammation[15](#bjs550227-bib-0015){ref-type="ref"}. The relative ratio of Tyr and Cl‐Tyr were calculated for each patient sample at T~0~ and T~end~, and results for the control and WHCO~2~ treatment groups were compared. Proteins in the tissue homogenates were hydrolysed to individual free amino acids[19](#bjs550227-bib-0019){ref-type="ref"}. Hydrolysed analytes were then purified by solid‐phase extraction and analysed on an Agilent 1290 series UHPLC system tandem with 6460A triple quadrupole mass spectrometer (Agilent Technologies, Santa Clara, California, USA). Analytes within the mixture were separated using an Agilent Zorbax Eclipse XDB‐C18 (4·6 × 5 mm, 1·8 μm) column fitted with a UPLC Zorbax Eclipse XDB‐C18 (4·6 × 5 mm, 1·8 μm) guard column, and with a mobile phase A containing 0·1 per cent formic acid (v/v) and mobile phase B containing 0·1 per cent formic acid (v/v) in 90 per cent acetonitrile and 10 per cent water (v/v). The gradient was started at 2 per cent of mobile phase B and increased to 10 per cent at 3 min, continuing to increase to 95 per cent over 4 min and maintained for 1 min, and then returned to 2 per cent at 15 min for 1 min of equilibration. Tandem mass spectrometry was performed using electrospray ionization equipped with jet stream technology in the positive mode. The gas temperature was optimized at 350°C with a flow of 12 l/min, and the sheath gas was at 375°C with a flow of 11 l/min. Capillary voltage was 3500 MeV, and the nebulizer pressure was 25 p.s.i. All analytes were detected in multiple reaction monitoring mode with fragment voltage at 135 V, using nitrogen as the collision gas. For each analyte, one quantitative transition and one qualitative transition were monitored, including the internal standard. Data acquisition was performed using MassHunter B.07.01 (Agilent Technologies), and data analysis was conducted using the accompanied MassHunter Qualitative and Quantitative B.07.00 (Agilent Technologies).

### *Light microscopy* {#bjs550227-sec-0017}

Peritoneal architecture was examined by light microscopy after staining with haematoxylin and eosin. This approach has been used previously to assess peritoneal effacement[20](#bjs550227-bib-0020){ref-type="ref"}, [21](#bjs550227-bib-0021){ref-type="ref"}, [22](#bjs550227-bib-0022){ref-type="ref"}, [23](#bjs550227-bib-0023){ref-type="ref"}, [24](#bjs550227-bib-0024){ref-type="ref"}. Images were obtained using a Zeiss Axio AX10 light microscope (Carl Zeiss) with a digital camera output (Zeiss Axiocam 105 color; Carl Zeiss). The stained images were assessed independently by five pathologists at the University of Sydney Medical School, all blinded to sample assignment; their results were combined, analysed and quantified.

Postoperative outcomes {#bjs550227-sec-0018}
----------------------

Postoperative outcomes, including postoperative pain (morphine equivalent daily dose score), duration of patient‐controlled analgesia use (measured in days), duration of hospital stay (measured in days), time to return to bowel function (flatus, stool), commencement of diet, clinical complications (persistent ileus (defined as: failure of the patient to eat, pass flatus or evacuate the bowel within 5 days of laparotomy), anastomotic leak, wound infection, unexpected return to theatre, unexpected readmission, and complications, graded according to Clavien--Dindo classification[25](#bjs550227-bib-0025){ref-type="ref"}) were collated and analysed. Patients were followed up for 60 days from the date of discharge, by telephone interviews as well as in day clinics.

Statistical analysis {#bjs550227-sec-0019}
--------------------

Sample size calculations were performed using the standard deviation of the measure of oxidative stress, Cl‐Tyr[26](#bjs550227-bib-0026){ref-type="ref"}, [27](#bjs550227-bib-0027){ref-type="ref"}, [28](#bjs550227-bib-0028){ref-type="ref"}, [29](#bjs550227-bib-0029){ref-type="ref"}. For a power of 80 per cent, at 5 per cent two‐sided significance, the sample size was 40 patients.

Data were analysed using IBM SPSS® version 23 (IBM, Armonk, New York, USA) and GraphPad Prism® version 7.0 (GraphPad Software, La Jolla, California, USA). Continuous variables were tested using the D\'Agostino--Pearson test. Groups were compared with *t* tests or two‐way ANOVA, using Tukey\'s multiple comparison test for parametric continuous variables and the Mann--Whitney *U* test for non‐parametric continuous variables (tissue cytokines and chemokines, and apoptosis assays). The level of significance for all tests was set at *P* \< 0·050.

Results {#bjs550227-sec-0020}
=======

Between February 2013 and December 2016, 40 patients were recruited for the trial and randomly allocated into two groups, each of 20 subjects. However, one patient assigned to the control group withdrew from the study due to preoperative pulmonary embolism, leaving 20 patients in the WHCO~2~ group and 19 in the control group (*Fig*. [1](#bjs550227-fig-0001){ref-type="fig"}). All data for the 39 patients were collected.

![CONSORT diagram for the trial WHCO~2~, warmed, humidified carbon dioxide.](BJS5-4-45-g001){#bjs550227-fig-0001}

Demographics {#bjs550227-sec-0021}
------------

Of the 39 patients enrolled in the study, 15 were women and the mean age was 60·9 (95 per cent c.i. 55·9 to 66·0; range 32--87) years (*Table* [1](#bjs550227-tbl-0001){ref-type="table"}). Mean BMI was 26·5 (95 per cent c.i. 24·1 to 28·9; range 14·2--43·1) kg/m^2^. Seventeen patients were overweight or obese (BMI above 25 kg/m^2^). Nine patients were smokers. There were no significant differences between the groups in age, sex, obesity, background medical history (including ischaemic heart disease, diabetes, hypertension, COPD and chronic renal failure), ASA fitness grade, smoking status, mobility, preoperative haemoglobin level and coagulation level (measured as the international normalized ratio). Eighteen patients had surgery for malignancy, six in the control group and 12 in the WHCO~2~ group, but there was no difference in the indication for surgery (*P* = 0·075).

###### 

Demographics of patients in the carbon dioxide and control groups

                                                        Control group (*n* = 19)   Carbon dioxide group (*n* = 20)   *P* [\*](#bjs550227-note-0003){ref-type="fn"}
  ---------------------------------------------------- -------------------------- --------------------------------- -----------------------------------------------
  **Age (years)**                                                                                                   
  Mean                                                            60·5                          61·4                 0·863[†](#bjs550227-note-0101){ref-type="fn"}
  Median (i.q.r.)                                          55·0 (48·0--77·5)              61·5 (56·5--70·7)         
  **Sex ratio (M** : **F)**                                     (12 : 7)                      (12 : 8)                                   0·839
  **BMI (kg/m** ^**2**^ **)**                                                                                       
  Mean                                                            27·7                          25·4                 0·334[†](#bjs550227-note-0101){ref-type="fn"}
  Median (i.q.r.)                                          27·6 (21·1--34·4)              23·0 (21·0--26·6)         
  **BMI \> 25 kg/m** ^**2**^                                       10                             7                                      0·130
  **IHD**                                                          2                              4                                      0·339
  **COPD**                                                         0                              1                                      0·299
  **Mean eGFR (ml per min per 1·73 m** ^**2**^ **)**              73·4                          81·9                 0·124[†](#bjs550227-note-0101){ref-type="fn"}
  **Diabetes mellitus**                                            4                              5                                      0·640
  **Hypertension**                                                 7                             10                                      0·267
  **Any co‐morbidity**                                             8                             12                                      0·148
  **No. of co‐morbidities**                                                                                         
  Mean                                                            0·7                            1·1                 0·332[†](#bjs550227-note-0101){ref-type="fn"}
  Median (i.q.r.)                                              0 (0--1·5)                     1 (0--2)              
  **ASA grade**                                                                                                                          0·600
  I--II                                                            7                              9                 
  III--IV                                                          12                            11                 
  **Preoperative haemoglobin level (g/dl)**                                                                         
  Mean                                                           130·7                          125·1                0·485[†](#bjs550227-note-0101){ref-type="fn"}
  Median (i.q.r.)                                          137 (116·5--151·0)            128 (117·5--136·5)         
  **Preoperative INR**                                                                                              
  Mean                                                            1·0                            1·1                 0·562[†](#bjs550227-note-0101){ref-type="fn"}
  Median (i.q.r.)                                             1 (1·0--1·2)                  1 (1·0--1·1)            
  **Anticoagulants**                                               4                              5                                      0·770
  **Smoker**                                                       6                              3                                      0·219
  **Mobility (4 flights of stairs)**                               14                            12                                      0·365
  **Pathology/indication for surgery**                                                                              
  Malignant disease                                                6                             12                                      0·075
  Benign disease                                                   13                             8                 
  ECF/parastomal hernia                                            3                              1                 
  Reversal stoma                                                   3                              5                 
  IBD                                                              4                              2                 
  Diverticular disease                                             1                              0                 
  Bowel fistula                                                    2                              0                 

IHD, ischaemic heart disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; INR, international normalized ratio; ECF, enterocutaneous fistula; IBD, inflammatory bowel disease.

Pearson\'s χ^2^ test, except

Student\'s *t* test.

Surgical procedures {#bjs550227-sec-0022}
-------------------

Procedures included abdominoperineal, high anterior, low anterior and ultralow anterior resections (*Table* [2](#bjs550227-tbl-0002){ref-type="table"}). Other procedures included reversal of Hartmann\'s procedure, repair of enterocutaneous fistula, repair of parastomal hernia, pelvic exenteration, and resection of retroperitoneal colorectal cancer recurrence.

###### 

Surgical procedures performed

                                 Control group   Carbon dioxide group
  ----------------------------- --------------- ----------------------
  Rectal resection                     8                  4
  Ileocolic resection                  3                  4
  Small bowel resection                1                  1
  Total or subtotal colectomy          1                  2
  Other procedure                      8                  10

Some patients had more than one resection during the same operation.

Inflammatory cytokines and chemokines {#bjs550227-sec-0023}
-------------------------------------

Levels of inflammatory cytokines and chemokines increased from the beginning to the end of the operation. When WHCO~2~ and control groups were combined and analysed together, a significant increase was observed from T~0~ to T~end~ for interleukin (IL) 1α, IL‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8, IL‐10, IL‐13, IL‐15, IL‐17, monocyte chemotactic protein (MCP) 1, RANTES (regulated on activation, normal T‐cell expressed and secreted) and growth‐regulated oncogene (GRO) α (*Table* [3](#bjs550227-tbl-0003){ref-type="table"}). There was no significant difference between the groups in any cytokine/chemokine level at T~0~ (*Fig*. [2](#bjs550227-fig-0002){ref-type="fig"}). In the control group, a significant increase was seen from T~0~ to T~end~ in IL‐1β (4·2‐fold; *P* = 0·026), IL‐8 (14·5‐fold; *P* = 0·006), IL‐10 (8·5‐fold; *P* = 0·006), IL‐17 (8·0‐fold; *P* = 0·006), MCP‐1 (19·3‐fold; *P* \< 0·001) and GROα (8·2‐fold; *P* = 0·037). In the WHCO~2~ group, there were significant increases for IL‐2 (from 3·5‐ to 17·8‐fold; *P* = 0·047), IL‐8 (from 1·2‐ to 15·5‐fold; *P* = 0·004), IL‐10 (from 1·3‐ to 11‐fold; *P* = 0·004), IL‐17 (from 1·4‐ to 7·1‐fold; *P* = 0·045), MCP‐1 (from 0·9‐ to 25·4‐fold; *P* \< 0·001) and GROα (from 1·0‐ to 10·0‐fold; *P* = 0·003) (*Fig*. [2](#bjs550227-fig-0002){ref-type="fig"}). In contrast, comparison of the fold change in inflammatory cytokines and chemokines for the control and WHCO~2~ groups using log(T~end~/T~0~) found statistically significant differences only for IL‐2 (5·3 *versus* 2·8; *P* = 0·028) and IL‐4 (3·5 *versus* 2·0; *P* = 0·041) (*Table* [4](#bjs550227-tbl-0004){ref-type="table"}).

###### 

Fold change increases in cytokine/chemokine levels

            Fold increase from T~0~ to T~end~   *P* [\*](#bjs550227-note-0006){ref-type="fn"}
  -------- ----------------------------------- -----------------------------------------------
  IL‐1α                    2·1                                      0·009
  IL‐1β                    3·2                                      0·002
  IL‐2                     6·0                                    \< 0·001
  IL‐4                     2·4                                      0·021
  IL‐5                     3·0                                      0·002
  IL‐6                    135·2                                   \< 0·001
  IL‐8                    13·8                                    \< 0·001
  IL‐10                    8·3                                    \< 0·001
  IL‐12                    1·3                                      0·120
  IL‐13                    4·4                                      0·004
  IL‐15                    4·2                                      0·011
  IL‐17                    6·4                                    \< 0·001
  TNF‐α                    1·3                                      0·149
  IFN‐γ                    1·0                                      0·902
  MCP‐1                   24·2                                    \< 0·001
  RANTES                   1·2                                      0·031
  GROα                     7·9                                    \< 0·001
  IP‐10                    1·5                                      0·234

IL, interleukin; TNF, tumour necrosis factor; IFN, interferon; MCP, monocyte chemotactic protein; RANTES, regulated on activation, normal T‐cell expressed and secreted; GRO, growth‐regulated oncogene; IP, inducible protein.

Unpaired *t* test.

![Change in levels of cytokines/chemokines in carbon dioxide and control groups Fold change in inflammatory cytokines and chemokines at the start (T~0~) and end (T~end~) of the operation in control and warmed, humidified carbon dioxide (WHCO~2~) groups: **a** interleukin (IL) 1α; **b** IL‐1β; **c** IL‐2; **d** IL‐4; **e** IL‐6; **f** IL‐8; **g** IL‐10; **h** IL‐12; **i** IL‐17; **j** IL‐13; **k** tumour necrosis factor (TNF) α; **l** monocyte chemotactic protein (MCP) 1; **m** RANTES (regulated on activation, normal T‐cell expressed and secreted); **n** growth‐regulated oncogene (GRO) α; **o** inducible protein (IP) 10. Values are mean(s.e.m.). \**P* \< 0·050, †*P* \< 0·010, ‡*P* \< 0·001 (ANOVA using Tukey\'s multiple comparison test).](BJS5-4-45-g002){#bjs550227-fig-0002}

###### 

Comparison of increase in cytokine/chemokines measured using log(T~end~/T~0~)

            Log(T~end~/T~0~)   *P* [\*](#bjs550227-note-0008){ref-type="fn"}  
  -------- ------------------ ----------------------------------------------- -------
  IL‐1α           2·6                               1·4                        0·178
  IL‐1β           3·3                               1·0                        0·178
  IL‐2            5·3                               2·8                        0·028
  IL‐4            3·5                               2·0                        0·041
  IL‐5            2·7                               3·4                        0·990
  IL‐6            8·6                               7·4                        0·363
  IL‐8            5·0                               4·1                        0·805
  IL‐10           3·4                               3·8                        0·635
  IL‐12           0·9                               1·4                        0·691
  IL‐13           2·7                               3·5                        0·539
  IL‐15           3·7                               4·3                        0·675
  IL‐17           5·0                               3·2                        0·244
  TNF‐α           1·6                               1·3                        0·973
  IFN‐γ           0·7                               2·1                        0·417
  MCP‐1           4·0                               4·8                        0·112
  RANTES          0·4                               0·4                        0·961
  GROα            3·1                               3·8                        0·258
  IP‐10           0·4                               0·9                        0·232

IL, interleukin; TNF, tumour necrosis factor; IFN, interferon; MCP, monocyte chemotactic protein; RANTES, regulated on activation, normal T‐cell expressed and secreted; GRO, growth‐regulated oncogene; IP, inducible protein.

Mann--Whitney *U* test.

Apoptosis assays {#bjs550227-sec-0024}
----------------

Apoptosis showed a twofold increase (95 per cent c.i. 1·1 to 2·9; *P* = 0·028) in the combined data cohort from T~0~ to T~end~. When considered separately, the control group showed a borderline increase in caspase‐3/7 activity (*P* = 0·050), whereas there was no significant change in caspase activity for the WHCO~2~ group (*P* = 0·883) (*Fig*. [3](#bjs550227-fig-0003){ref-type="fig"}). However, analysis of the change in caspase‐3,7 activity by log(T~end~/T~0~) revealed no difference between control and WHCO~2~ groups (0·5 *versus* 1·2 respectively; *P* = 0·120).

![Change in degree of apoptosis in isolated peritoneal tissue Fold change in caspase‐3/7 activity in control and warmed, humidified carbon dioxide (WHCO~2~) groups at the start (T~0~) and end (T~end~) of the operation. Values are mean(s.e.m.). \**P* ≤ 0·050 (ANOVA using Tukey\'s multiple comparison test).](BJS5-4-45-g003){#bjs550227-fig-0003}

*Fig*. [4](#bjs550227-fig-0004){ref-type="fig"} shows a diffuse green fluorescence and DAPI staining along the peritoneal edges of the section. In the combined cohort, cells comprising the peritoneal edges showed evidence of apoptosis in five of the 39 samples at T~0~, increasing to 23 of all 39 samples at T~end~. Comparison of the control and WHCO~2~ groups at T~end~ demonstrated that green fluorescence indicative of apoptosis was visible along the peritoneal edge in nine of the 19 control samples, a proportion slightly lower than the ten of 20 seen for the WHCO~2~ group (*P* = 0·869).

![TUNEL assay of peritoneal edges Red arrows indicate areas of fluorescence green (apoptosis/necrosis) along the peritoneal edge. TUNEL, terminal deoxynucleotidyl transferase‐mediated dUTP nick‐end labelling.](BJS5-4-45-g004){#bjs550227-fig-0004}

Tissue 3‐chlorotyrosine/tyrosine ratio {#bjs550227-sec-0025}
--------------------------------------

The mean level of chlorinated tyrosine residues (as expressed by the Cl‐Tyr/Tyr ratio) was 4·3 for the WHCO~2~ group at T~0~, decreasing to 3·1 at T~end~. The corresponding evaluation for the control group revealed an increase in the ratio, from 2·3 at T~0~ to 3·6 at T~end~.

The relative levels of Cl‐Tyr/Tyr at T~end~ were re‐expressed as a fraction of those at T~0~: 3·1 (95 per cent c.i. 0·0 to 6·1) in the control group *versus* 1·1 (0·2 to 1·9) in the WHCO~2~ group (*P* = 0·036) (*Fig*. [5](#bjs550227-fig-0005){ref-type="fig"}). Accordingly, for the WHCO~2~ group the Cl‐Tyr/Tyr ratio had increased by 1·1‐fold at T~end~, compared with the corresponding ratio measured at T~0~, whereas for the control group the ratio increased by a higher 3·1‐fold change from T~0~ to T~end~.

![Change in level of oxidative damage in control and carbon dioxide groups Fold change in 3‐chlorotyrosine/tyrosine ratio (Cl‐Tyr/Tyr) from the start (T~0~) to the end (T~end~) of the operation in warmed, humidified carbon dioxide (WHCO~2~) and control groups. Values are mean(s.e.m.). \**P* \< 0·050 (Mann--Whitney *U* test).](BJS5-4-45-g005){#bjs550227-fig-0005}

Light microscopy {#bjs550227-sec-0026}
----------------

Representative haematoxylin and eosin‐stained peritoneal images are shown in *Figs* [6](#bjs550227-fig-0006){ref-type="fig"} and [7](#bjs550227-fig-0007){ref-type="fig"}. *Fig*. [6](#bjs550227-fig-0006){ref-type="fig"} shows visible peritoneum, whereas *Fig*. [7](#bjs550227-fig-0007){ref-type="fig"} shows denudation of the peritoneum with evidence of recruitment and infiltration of leucocytes. In the combined total cohort, peritoneum was visible in 36 of the 39 specimens collected at T~0~, whereas identification of visible peritoneum decreased to 30 of 39 at T~end~. By contrast, comparison of the control and WHCO~2~ groups at T~end~ revealed that peritoneum was visible in only 11 of 19 samples from the control group *versus* 19 of 20 samples in the WHCO~2~ group (*P* = 0·006).

![Visible peritoneum Haematoxylin and eosin‐stained section showing visible peritoneal edge (blue arrows).](BJS5-4-45-g006){#bjs550227-fig-0006}

![Peritoneal damage Haematoxylin and eosin‐stained sections showing denudation of the peritoneum (blue arrows). The last three images also show white cell infiltration of the peritoneum (green arrows).](BJS5-4-45-g007){#bjs550227-fig-0007}

Surgical outcome {#bjs550227-sec-0027}
----------------

There were no significant differences between the control and WHCO~2~ groups with respect to duration of surgery, number of surgical assistants, intraoperative complications, stoma formation or number of patients assigned to the ERAS protocol (*Table* [5](#bjs550227-tbl-0005){ref-type="table"}). Intraoperative blood transfusion was significantly greater in the WHCO~2~ group (6 of 20 patients *versus* 1 of 19 in the control group; *P* = 0·044).

###### 

Summary of intraoperative and perioperative outcomes

                                                                                                Total (*n* = 39)   Control group (*n* = 19)   Carbon dioxide group (*n* = 20)   *P* [†](#bjs550227-note-0010){ref-type="fn"}
  -------------------------------------------------------------------------------------------- ------------------ -------------------------- --------------------------------- -----------------------------------------------
  **Duration of surgery (min)** [\*](#bjs550227-note-0009){ref-type="fn"}                            288·6                  284·1                          292·9                0·851[‡](#bjs550227-note-0102){ref-type="fn"}
  **No. of assistants** [\*](#bjs550227-note-0009){ref-type="fn"}                                     2·1                    1·8                            2·3                 0·272[‡](#bjs550227-note-0102){ref-type="fn"}
  **Duration of exposure to carbon dioxide (min)** [\*](#bjs550227-note-0009){ref-type="fn"}                                  --                           203·7                                     --
  **Volume of carbon dioxide (litres)** [\*](#bjs550227-note-0009){ref-type="fn"}                                             --                           2037                                      --
  **Intraoperative blood transfusion**                                                                 7                      1                              6                                      0·044
  **Intraoperative complications**                                                                     7                      2                              5                                      0·239
  **ERAS protocol**                                                                                    13                     7                              6                                      0·651
  **Stoma formation**                                                                                  14                     4                             10                                      0·060
  End colostomy                                                                                                               1                              3                 
  Loop ileostomy                                                                                                              2                              4                 
  End ileostomy                                                                                                               1                              3                 
  **Duration of hospital stay (days)** [\*](#bjs550227-note-0009){ref-type="fn"}                      15·9                   15·1                          16·6                 0·760[‡](#bjs550227-note-0102){ref-type="fn"}
  **Time to passage of flatus (days)** [\*](#bjs550227-note-0009){ref-type="fn"}                      3·7                    5·0                            2·5                 0·008[‡](#bjs550227-note-0102){ref-type="fn"}
  **Time to passage of stool (days)** [\*](#bjs550227-note-0009){ref-type="fn"}                       4·6                    5·5                            3·7                 0·092[‡](#bjs550227-note-0102){ref-type="fn"}
  **Commenced on clear/free fluids (days)** [\*](#bjs550227-note-0009){ref-type="fn"}                 3·4                    4·3                            2·5                 0·077[‡](#bjs550227-note-0102){ref-type="fn"}
  **Commenced on light diet (days)** [\*](#bjs550227-note-0009){ref-type="fn"}                        5·9                    6·9                            4·9                 0·125[‡](#bjs550227-note-0102){ref-type="fn"}
  **Unexpected return to theatre**                                                                     7                      4                              3                                      0·622
  **Unexpected readmission**                                                                           7                      3                              4                                      0·732
  **Postoperative ileus**                                                                              11                     8                              3                                      0·074
  **30‐day mortality**                                                                                 0                      0                              0                                       --
  **Wound infection**                                                                                  9                      6                              3                                      0·219
  **Anastomotic leak**                                                                                 1                      0                              1                                       --
  **Clavien--Dindo complication grade**                                                                                                                                        
  I                                                                                                    21                     12                             9                                      0·256
  II                                                                                                   8                      4                              4                                      0·935
  III--IV                                                                                              9                      4                              5                                      0·770

Values are mean. ERAS, enhanced recovery after surgery.

Pearson\'s χ^2^ test, except

Student\'s *t* test.

For the whole cohort, the mean duration of hospital admission was 15·9 (median 11, 95 per cent c.i. 10·6 to 21·2; range 3--77) days. Postoperative ileus occurred in 11 of the 39 patients. Wound infection developed in nine patients, and one of 30 patients with a bowel anastomosis subsequently developed an anastomotic leak. Seven patients had unexpected readmission after discharge from hospital: two for wound infection, one for a small bowel obstruction, one for perforated stomach, one for constipation due to narrowed colorectal anastomosis, one because of high‐output ileostomy dysfunction and one for a pelvic collection requiring drainage. No 30‐day mortality was reported (*Table* [5](#bjs550227-tbl-0005){ref-type="table"}).

There was no difference between the two groups in duration of hospital stay or postoperative complications including wound infection, anastomotic leak, unexpected return to operating theatre and unexpected hospital readmission (*Table* [5](#bjs550227-tbl-0005){ref-type="table"}). Patients in the WHCO~2~ group passed flatus significantly earlier than those in the control group (mean 2·5 *versus* 5·0 days respectively; *P* = 0·008).

Discussion {#bjs550227-sec-0028}
==========

Inflammation is a tightly controlled process with factors that are proinflammatory and anti‐inflammatory working simultaneously[30](#bjs550227-bib-0030){ref-type="ref"}. Whether localized peritoneal damage will promote a cascade of inflammation to the remaining bowel peritoneum is unclear; however, studies have shown that peritoneal damage is a feature occurring in animals and humans undergoing laparoscopy/laparotomy[30](#bjs550227-bib-0030){ref-type="ref"}.

Human and animal studies have found discrepant results regarding the effect of warmed, humidified carbon dioxide on peritoneal inflammation[30](#bjs550227-bib-0030){ref-type="ref"}. In laparoscopic human studies, it was reported[31](#bjs550227-bib-0031){ref-type="ref"} that peritoneal damage was less with the use of warmed, humidified carbon dioxide gas insufflation, but another study[32](#bjs550227-bib-0032){ref-type="ref"} documented no difference. Similarly, animal‐based studies have shown that use of warmed, humidified carbon dioxide resulted in less peritoneal damage and desquamation[21](#bjs550227-bib-0021){ref-type="ref"}, [22](#bjs550227-bib-0022){ref-type="ref"}, [33](#bjs550227-bib-0033){ref-type="ref"}, whereas other studies found no effect[23](#bjs550227-bib-0023){ref-type="ref"}, [34](#bjs550227-bib-0034){ref-type="ref"}, [35](#bjs550227-bib-0035){ref-type="ref"}. A recently published animal‐based study[8](#bjs550227-bib-0008){ref-type="ref"} comparing the effect of warmed, humidified carbon dioxide during open abdominal surgery in mice *versus* passive airflow found significantly lower peritoneal tissue damage (as determined by cellular retraction, bulging, microvilli loss) in the WHCO~2~ group. In addition, peritoneal hypoxia, as measured by hypoxia‐inducible factor 1α concentration, was significantly lower in the WHCO~2~ group. This study[8](#bjs550227-bib-0008){ref-type="ref"} also found that core body temperature was maintained better in the WHCO~2~ group.

The present study evaluated oxidative stress on the peritoneum during laparotomy by measuring Cl‐Tyr as a fraction of native tyrosine. Oxidative stress during laparoscopy has been described previously[36](#bjs550227-bib-0036){ref-type="ref"}, and has been suggested to be due in part to the pneumoperitoneum leading to an increase in intra‐abdominal pressure contributing to organ ischaemia with resultant formation of reactive oxygen species (ROS). These ROS then damage the membrane phospholipids, proteins and DNA, resulting in cellular injury. Other authors[36](#bjs550227-bib-0036){ref-type="ref"} have hypothesized that, although raised intra‐abdominal pressure during laparoscopy (with resultant insufflation--deflation causing ischaemia--reperfusion injury) is contributory to oxidative stress, other factors could also contribute and interplay, such as anaesthesia, the surgical insult itself, patient position and the type of gas used. In addition, during laparotomy, where the peritoneum is exposed to the atmospheric conditions, factors contributing to oxidative stress could be desiccation, surgical insult and anaesthesia. Another systematic review[37](#bjs550227-bib-0037){ref-type="ref"} found that the increase in oxidative stress was less in the laparoscopic than in the laparotomy group, despite both groups showing a marked increase in plasma levels of markers of oxidative stress. However, most of these studies were based on plasma‐based measurement of oxidative stress; only a few studies measured oxidative stress in tissue specimens (including tissue malondialdehyde concentration and gastric mucosal pH).

The reason for the greater oxidative stress observed in open surgery compared with laparoscopic procedures remains unclear. A possible explanation could be in relation to peritoneal dessication, with peritoneal dessication and activation of neutrophils leading to ROS damage to the peritoneum, which may be more marked in open surgery.

An important question derived from this study is whether the positive outcome of warmed, humidified carbon dioxide is sufficiently rigorous to demand translation into clinical practice. In this study the carbon dioxide treatment group achieved earlier passage of flatus, although the procedures were heterogeneous. Overall, the postoperative outcomes in the two groups were comparable and no other significant difference was noted. It would be interesting to note in future whether use of warmed, humidified carbon dioxide would result in a lower rate of adhesion formation. However, this study was neither designed nor powered to detect differences in adhesion formation between the intervention and control groups, nor to detect clinical difference.

Nonetheless, this trial in humans can act as a pilot for a larger study, as there were no significant technical drawbacks to the use of low‐level carbon dioxide infusion. Placement of the diffuser did not interfere with the operation and therefore had no impact on duration of surgery. Future studies involving warmed, humidified carbon dioxide could investigate its effect on intraoperative splanchnic blood flow. Warmed, humidified carbon dioxide would raise local temperature, prevent heat loss through convection, and lower local pH, thereby increasing bowel perfusion. This would be especially beneficial when bowel anastomosis was being performed, as adequate perfusion is essential for anastomotic healing. Examination of the inhibition of peritoneal oxidative damage by inhibition of myeloperoxidase may be another useful study.
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